Jump to main content
Jump to site search

Issue 19, 2014
Previous Article Next Article

PET/SPECT imaging agents for neurodegenerative diseases

Author affiliations

Abstract

Single photon emission computed tomography (SPECT) or positron emission computed tomography (PET) imaging agents for neurodegenerative diseases have a significant impact on clinical diagnosis and patient care. The examples of Parkinson's Disease (PD) and Alzheimer's Disease (AD) imaging agents described in this paper provide a general view on how imaging agents, i.e. radioactive drugs, are selected, chemically prepared and applied in humans. Imaging the living human brain can provide unique information on the pathology and progression of neurodegenerative diseases, such as AD and PD. The imaging method will also facilitate preclinical and clinical trials of new drugs offering specific information related to drug binding sites in the brain. In the future, chemists will continue to play important roles in identifying specific targets, synthesizing target-specific probes for screening and ultimately testing them by in vitro and in vivo assays.

Graphical abstract: PET/SPECT imaging agents for neurodegenerative diseases

Back to tab navigation

Publication details

The article was received on 27 Nov 2013 and first published on 28 Mar 2014


Article type: Tutorial Review
DOI: 10.1039/C3CS60430F
Citation: Chem. Soc. Rev., 2014,43, 6683-6691
  •   Request permissions

    PET/SPECT imaging agents for neurodegenerative diseases

    L. Zhu, K. Ploessl and H. F. Kung, Chem. Soc. Rev., 2014, 43, 6683
    DOI: 10.1039/C3CS60430F

Search articles by author

Spotlight

Advertisements